A Randomized Controlled Trial Comparing Soy-Pea Protein to Animal Protein in Adults with Crohns Disease

In a randomized controlled trial involving adults with Crohn's disease, a 7-day diet replacing animal protein with soy-pea protein demonstrated significant anti-inflammatory benefits, particularly in reducing fecal myeloperoxidase and improving disease activity scores among participants with lower baseline disease activity.

The Gist

The Big Picture: Swapping the Fuel

Imagine your gut is a busy factory. In people with Crohn's disease, this factory is prone to catching fire (inflammation). The researchers wanted to see if changing the "fuel" the factory runs on could help put out those fires.

Specifically, they asked: What happens if we swap the factory's usual fuel (animal protein like meat and dairy) for a plant-based fuel (soy and pea protein)?

They didn't change the rest of the diet (no vegetables, no carbs, no fats were added or removed); they only swapped the protein source. They tested this on 60 people (31 with Crohn's and 29 healthy people) for just 7 days.

The Experiment: The 7-Day Swap

Think of this like a "taste test" for your gut health, but with strict rules.

• The Setup: Everyone ate exactly the same meals provided by the hospital. The only difference was the protein source.
  • Group A (AnimalP): Ate meals with meat, eggs, or dairy protein.
  • Group B (SoyP): Ate meals with soy and pea protein.
• The Goal: To see if the plant-based fuel made the factory (the gut) less angry and less inflamed.

The Results: The Plant Fuel Worked Better

After one week, the results showed that the "Plant Fuel" group had a much calmer factory.

1. The Smoke Detectors Went Quiet
Scientists use "smoke detectors" to measure inflammation in the gut. Two main detectors were used:

• MPO (Myeloperoxidase): Think of this as a smoke alarm that goes off when white blood cells are rushing to fight a fire in the gut.
• CDAI/HBI: These are like the "complaint forms" patients fill out about their pain and bathroom habits.

The Findings:

• People eating the Soy/Pea diet saw their "smoke alarms" (MPO) go down significantly. Their gut inflammation dropped.
• People eating the Animal diet didn't see this drop; in fact, their inflammation stayed the same or got slightly worse.
• The "Complaint Forms": People on the Soy/Pea diet reported feeling better (less pain, fewer bathroom issues) much more often than those on the Animal diet.

2. Who Benefited the Most?
The study found that the "Plant Fuel" worked best for people whose factory was already mostly quiet but still had a little bit of smoke (people with mild disease or those in remission).

• Analogy: It's like using a fire extinguisher on a small smoldering ember—it puts it out completely. But if the factory is already on fire (severe active disease), one week of plant protein wasn't enough to put the whole blaze out, though it didn't make it worse either.

3. The "Germ-Free Mouse" Test
To prove that the gut bacteria were the ones causing the change, the researchers did a clever experiment. They took poop samples from the humans and put them into special germ-free mice.

• The Result: The mice that received poop from the Soy/Pea humans stayed healthy and didn't get inflamed. The mice that received poop from the Animal humans got inflamed.
• The Takeaway: This proves that the plant-based diet actually changed the "crew" of bacteria living in the gut to be more peaceful and less likely to start fires.

Safety and Taste

• Safety: The plant-based diet was very safe. Almost no one got sick, and the few side effects (like a little gas) went away quickly.
• Taste: When the study ended, most people said they were happy to keep eating the Soy/Pea meals. It wasn't a "yucky" diet; people actually liked it.

The Bottom Line

This study is like a short-term trial run. It showed that for people with Crohn's disease, simply swapping meat/dairy protein for soy/pea protein for just one week can:

1. Lower the "smoke" (inflammation) in the gut.
2. Make people feel less pain.
3. Change the gut bacteria to be more helpful.

Important Note: The study only lasted 7 days. It tells us the switch can work quickly, but it doesn't tell us if eating this way for years will cure the disease or prevent future flares. It just proves that the plant-based protein is a safe and effective tool to calm the gut down in the short term.

Technical Summary

Technical Summary: A Randomized Controlled Trial Comparing Soy-Pea Protein to Animal Protein in Adults with Crohn's Disease

Problem Statement
Crohn's disease (CD) is a chronic, incurable inflammatory bowel disease characterized by periods of relapse and remission. Current therapeutic strategies often fail to control residual subclinical inflammation, which is associated with subsequent disease flares and loss of therapeutic response. While dietary interventions like Exclusive Enteral Nutrition (EEN) show promise in pediatric populations, there is a need for simpler, scalable dietary strategies that can modulate inflammation in adults. Preclinical murine models suggested that replacing animal protein with soy-pea protein reduces intestinal inflammation and improves gut barrier integrity. However, the efficacy of this specific protein substitution in humans with CD remained untested. This study addresses the gap between preclinical findings and clinical application by evaluating whether replacing animal protein with soy-pea protein in a controlled diet reduces the pro-inflammatory potential of gut microbiota and intestinal inflammation in CD patients.

Methodology
The study was an open-label, randomized controlled feeding trial (RCT) conducted at University Hospitals Cleveland Medical Center between November 2019 and November 2022.

• Participants: The study enrolled 60 participants (31 with CD and 29 healthy controls) after screening 572 CD individuals and 79 healthy controls. Participants were randomized 1:1 to consume either a soy-pea protein-based diet (SoyP) or an animal protein-based diet (AnimalP) for 7 consecutive days.
• Intervention: All meals and snacks were provided by the study to ensure strict adherence. The diets were identical in macronutrient composition, differing only in the protein source. Participants consumed the diet for 7 days following a 12-hour fast.
• Outcomes:
  • Primary: Absolute difference (Δd7-d0) in Crohn's Disease Activity Index (CDAI) score and fecal myeloperoxidase (MPO).
  • Secondary: Fecal calprotectin (FC), high-sensitivity C-reactive protein (hsCRP), Harvey Bradshaw Index (HBI), and short CDAI (sCDAI).
  • Microbiome & Mechanism: Fecal samples were analyzed via metagenome sequencing. Additionally, fecal microbiota transplantation (FMT) was performed from human participants into germ-free SAMP1/YitFC mice to assess the inflammatory potential of the diet-altered microbiota.
• Statistical Analysis: Comparisons utilized non-parametric tests (Wilcoxon, Mann-Whitney) and risk ratio analysis. A post-hoc rank-based composite CDAI-MPO score was constructed to integrate clinical and biomarker responses.

Key Contributions and Results

• Clinical Symptom Improvement: After 7 days, CD participants on the SoyP diet were significantly more likely to show reductions in HBI scores (RR=4.68, P=0.009) compared to the AnimalP group. While CDAI reductions showed a similar directional trend (RR=1.52, P=0.135), no participants experienced worsening of CDAI scores.
• Reduction in Inflammatory Biomarkers: The SoyP diet induced a significant reduction in fecal MPO in CD participants (75% reduction rate, P=0.009 within group), whereas the AnimalP group showed no significant change. Between-group analysis confirmed a significant difference in MPO reduction (P=0.003). Risk ratio analysis indicated CD-SoyP participants were 2.3 times more likely to experience MPO reduction than CD-AnimalP participants (P=0.032).
• Composite Score: A rank-based composite CDAI-MPO score was significantly lower (indicating better outcomes) in the CD-SoyP group compared to the CD-AnimalP group (median 5 vs. 8, P=0.012).
• Stratified Analysis: The beneficial effects were most pronounced in CD participants with lower baseline disease activity (CDAI <150), where the association between SoyP and MPO reduction was highly significant (P<0.0001). In participants with higher baseline activity (CDAI ≥150), the response was heterogeneous and non-significant.
• Microbiome Shifts: While alpha diversity did not change significantly, species-level analysis revealed that the SoyP diet enriched Roseburia hominis and reduced Paraprevotella xylaniphila and Streptococcus anginosus in CD participants. Functional pathway analysis showed enrichment in L-ornithine biosynthesis and the MEP pathway (anti-inflammatory) and a reduction in purine synthesis pathways (pro-inflammatory).
• Translational Evidence (FMT): Mice transplanted with fecal microbiota from CD participants who consumed the SoyP diet exhibited neutral or anti-inflammatory effects in a DSS-induced colitis model, whereas those receiving pre-diet or AnimalP microbiota did not show the same consistent benefit.
• Safety and Adherence: The diets were well-tolerated with no serious adverse events. Minor gastrointestinal symptoms (flatulence, bloating) resolved within 1-2 days. Adherence was high, with only one reported non-compliant food item.

Significance and Claims
The authors conclude that short-term replacement of animal protein with soy-pea protein within a controlled diet exerts a beneficial, anti-inflammatory effect in adults with Crohn's disease. The study demonstrates that protein source alone, without altering other macronutrients, can meaningfully influence inflammatory outcomes.

The paper claims that the greatest benefit is observed in patients with lower baseline disease activity (clinically quiescent but with residual subclinical inflammation), suggesting a potential role for soy-pea protein in maintaining remission or preventing relapse. The findings support the hypothesis that plant-based protein sources can shift the gut microbiome toward an anti-inflammatory state, a mechanism confirmed via FMT in murine models. The authors posit that targeted protein modification offers a scalable, acceptable, and biologically meaningful adjunctive strategy for inflammation control, warranting longer-term randomized controlled trials to evaluate sustained incorporation into habitual diets. The study emphasizes that these results are derived from a short-term, controlled feeding trial and should not be used to guide immediate clinical practice without further validation.